Literature DB >> 19047571

Management and treatment of glycogenosis type II.

B Bembi1, E Cerini, C Danesino, M A Donati, S Gasperini, L Morandi, O Musumeci, G Parenti, S Ravaglia, F Seidita, A Toscano, A Vianello.   

Abstract

Glycogenosis type II is a multisystem disorder that requires management by a multidisciplinary team. The team should include several specialists, such as a metabolic disease specialist or biochemical geneticist, cardiologist, pulmonologist, neurologist, neuromuscular specialist, intensivist, orthopedist, respiratory therapist, physical therapist, occupational therapist, otolaryngologist speech therapist, audiologist, genetic counselor, and a metabolic dietician, who, as a team, will be capable of addressing the different manifestations of the condition. Aspects of functional assessment, rehabilitation, nutritional management, care coordination, nursing, genetic counseling, prenatal diagnosis, and screening are discussed in this article. In addition, treatment of glycogenosis type II is reviewed with attention to emerging therapeutic options.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19047571     DOI: 10.1212/WNL.0b013e31818da93f

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

Review 1.  Enzyme replacement therapy for Pompe disease.

Authors:  Corrado Angelini; Claudio Semplicini
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

2.  Urge incontinence and gastrointestinal symptoms in adult patients with pompe disease: a cross-sectional survey.

Authors:  Nesrin Karabul; Anika Skudlarek; Janine Berndt; Cornelia Kornblum; Rudolf A Kley; Stephan Wenninger; Nikolaus Tiling; Eugen Mengel; Ursula Plöckinger; Matthias Vorgerd; Marcus Deschauer; Benedikt Schoser; Frank Hanisch
Journal:  JIMD Rep       Date:  2014-08-26

3.  Use of the muscle volume analyzer to evaluate enzyme replacement therapy in late-onset Pompe disease.

Authors:  Fuminobu Sugai; Yosuke Kokunai; Yoichi Yamamoto; Goichi Hashida; Kengo Shimazu; Masahito Mihara; Satoru Inoue; Saburo Sakoda
Journal:  J Neurol       Date:  2009-11-12       Impact factor: 4.849

4.  Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis.

Authors:  Thomas Hundsberger; Kai M Rösler; Oliver Findling
Journal:  J Neurol       Date:  2014-06-13       Impact factor: 4.849

5.  Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II.

Authors:  Bruno Bembi; Federica Edith Pisa; Marco Confalonieri; Giovanni Ciana; Agata Fiumara; Rossella Parini; Miriam Rigoldi; Arrigo Moglia; Alfredo Costa; Annalisa Carlucci; Cesare Danesino; Maria Gabriela Pittis; Andrea Dardis; Sabrina Ravaglia
Journal:  J Inherit Metab Dis       Date:  2010-09-14       Impact factor: 4.982

6.  Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease.

Authors:  Thomas Hundsberger; Marianne Rohrbach; Lukas Kern; Kai M Rösler
Journal:  J Neurol       Date:  2013-06-08       Impact factor: 4.849

7.  Abnormalities of cerebral arteries are frequent in patients with late-onset Pompe disease.

Authors:  Sabrina Sacconi; Jonathan D Bocquet; Stéphane Chanalet; Véronique Tanant; Leonardo Salviati; Claude Desnuelle
Journal:  J Neurol       Date:  2010-06-18       Impact factor: 4.849

8.  Sleep-Disordered Breathing and Effects of Noninvasive Ventilation in Patients with Late-Onset Pompe Disease.

Authors:  Matthias Boentert; Bianca Dräger; Christian Glatz; Peter Young
Journal:  J Clin Sleep Med       Date:  2016-12-15       Impact factor: 4.062

9.  Diagnostic efficacy of the fluorometric determination of enzyme activity for Pompe disease from dried blood specimens compared with lymphocytes-possibility for newborn screening.

Authors:  Zoltan Lukacs; Paulina Nieves Cobos; Eugen Mengel; Ralf Hartung; Michael Beck; Marcus Deschauer; Angelika Keil; René Santer
Journal:  J Inherit Metab Dis       Date:  2009-12-23       Impact factor: 4.982

10.  A case of galactosemia misdiagnosed as cow's milk intolerance.

Authors:  Roberto Della Casa; Carla Ungaro; Emma Acampora; Claudio Pignata; Pietro Vajro; Mariacarolina Salerno; Francesca Santamaria; Giancarlo Parenti
Journal:  Ital J Pediatr       Date:  2012-09-19       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.